You can buy or sell AngioDynamics and other stocks, options, ETFs, and crypto commission-free!
AngioDynamics, Inc. engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage. thrombolytic, and venous products. Read More The company was founded by Eamonn P. Hobbs in 1988 and is headquartered in Latham, NY.
Latham, New York
52 Week High
52 Week Low
Stock Valuation: AngioDynamics (NASDAQ: ANGO)
AngioDynamics is in the healthcare sector and is in the medical instruments and equipment industry. The company CEO is James C. Clemmer. AngioDynamics Inc designs, manufactures and sells medical, surgical and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Previous Intraday Trading Performance: The ANGO stock showed a previous change of 0.00% with an open at 22.10 and a close of 22.14. It reached a...
Simply Wall StMar 14
Is AngioDynamics, Inc. (NASDAQ:ANGO) Struggling With Its 3.9% Return On Capital Employed?
Today we’ll look at AngioDynamics, Inc. (NASDAQ:ANGO) and reflect on its potential as an investment. In particular, we’ll consider its Return On Capital Employed (ROCE), as that can give us insight into how profitably the company is able to employ capital in its business. First of all, we’ll work out how to calculate ROCE. Next, we’ll compare it to others in its industry. And finally, we’ll look at how its current liabilities are impacting its ROCE. What is Return On Capital Employed (ROCE)? ROCE is a me...
Associated PressMar 8
AngioDynamics Wins Patent Infringement Dispute With Bard
LATHAM, N.Y.--(BUSINESS WIRE)--Mar 8, 2019--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced that the United States District Court for the District of Delaware, on day four of a jury trial at the close of C.R. Bard’s case (Plaintiff), granted judgement as a matter of law under rule 50(a) in favor of AngioDynamics, dismissing Bard’s suit alleging that certain of AngioDynamics...
$0.22 per share
Available Apr 2, Pre-Market